A method for determining a numerical score representative of a patient's health, is characterized by the following steps. At an initial calibration step, a database is established from a series of indicators relating to the state of health of the patient, each indicator being assigned a numerical value, and afterwards a statistical analysis of this database is performed so as to establish for each of said indicators a score depending on a measured value of the indicators of the state of health with respect to reference values, and to establish at least four groups constituted by said indicators, each of said groups representing information corresponding respectively to oxidative stress, hereinafter Group 1; to functions of the digestive brain, hereinafter Group 2; to functions of the reptilian brain, hereinafter Group 3; and to physical abilities of the patient coupled to his information on his general state of health, hereinafter Group 4. Furthermore, a value is assigned to each group, then a health score S specific to the patient is calculated using the formula:

S=(Value Group 1+(2* Value Group 2)+(2* Value Group 3)+(3* Value Group 4))/(2* Number of groups)

A method for determining a numerical score representative of a patient's health, is characterized by the following steps. At an initial calibration step, a database is established from a series of indicators relating to the state of health of the patient, each indicator being assigned a numerical value, and afterwards a statistical analysis of this database is performed so as to establish for each of said indicators a score depending on a measured value of the indicators of the state of health with respect to reference values, and to establish at least four groups constituted by said indicators, each of said groups representing information corresponding respectively to oxidative stress, hereinafter Group 1; to functions of the digestive brain, hereinafter Group 2; to functions of the reptilian brain, hereinafter Group 3; and to physical abilities of the patient coupled to his information on his general state of health, hereinafter Group 4. Furthermore, a value is assigned to each group, then a health score S specific to the patient is calculated using the formula:

S=(Value Group 1+(2* Value Group 2)+(2* Value Group 3)+(3* Value Group 4))/(2* Number of groups)

A method of inhibiting or reducing inflammation in a mammal comprises administering MCP or similar Gal-3 binding moiety with honokiol in a range of about 8-10:1, by weight, MCP to honokiol. By pursuing complimentary pathways, a synergistic combination is achieved, where the reduction or degree of inflammation inhibition is greater than would be expected by the added administration of these two agents.

A method of inhibiting or reducing inflammation in a mammal comprises administering MCP or similar Gal-3 binding moiety with honokiol in a range of about 8-10:1, by weight, MCP to honokiol. By pursuing complimentary pathways, a synergistic combination is achieved, where the reduction or degree of inflammation inhibition is greater than would be expected by the added administration of these two agents.

A method of inhibiting or reducing inflammation in a mammal comprises administering MCP or similar Gal-3 binding moiety with honokiol in a range of about 8-10:1, by weight, MCP to honokiol. By pursuing complimentary pathways, a synergistic combination is achieved, where the reduction or degree of inflammation inhibition is greater than would be expected by the added administration of these two agents.

The present disclosure is in the field of pharmaceutical compositions suitable for the treatment of diseases in mammals. This application provides novel compositions and methods for treating various disorders or conditions that are associated with a dysfunctional intestinal microbiota. In particular, this application provides compositions and methods that can treat or cure gastrointestinal (GI) disorders such as Inflammatory Bowel Disease (IBD), including, for example, Crohn's Disease and ulcerative colitis.

Provided herein are methods for treating liver disorders, including non-alcoholic steatohepatitis (NASH), and symptoms and manifestations thereof, in a patient comprising administration of the SSAO inhibitor:

##STR00001##

or a pharmaceutically acceptable salt thereof.

Provided herein are methods for treating liver disorders, including non-alcoholic steatohepatitis (NASH), and symptoms and manifestations thereof, in a patient comprising administration of the SSAO inhibitor:

##STR00001##

or a pharmaceutically acceptable salt thereof.

The invention relates to compositions and formulations for managing weight in obese persons and individuals who wish to maintain their weight in a desired value regardless of their lifestyle habits or food preferences. The compositions comprise polymeric compounds that when administered as described herein form an intestinal overlay in situ which modulates the absorption of nutrients in the intestines for certain periods of time.

The invention relates to compositions and formulations for managing weight in obese persons and individuals who wish to maintain their weight in a desired value regardless of their lifestyle habits or food preferences. The compositions comprise polymeric compounds that when administered as described herein form an intestinal overlay in situ which modulates the absorption of nutrients in the intestines for certain periods of time.